Cigna Corp vs VanEck Rare Earth/Strategic Metals — how do they compare? Cigna Corp trades at $300.09 (market cap $80.25B), while VanEck Rare Earth/Strategic Metals trades at $78.22. The key difference: Cigna Corp pays a 2.06% dividend while VanEck Rare Earth/Strategic Metals pays none, and Cigna Corp is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| CI | REMX | |
|---|---|---|
Market Cap | $80.25B | — |
Sector | Health | Sector/Thematic |
52-Week High | $311.00 | $109.53 |
52-Week Low | $244.41 | $47.36 |
Enterprise Value | $103.35B | — |
Dividend Yield | 2.06% | — |
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $304.50, up 3.76% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.91 and P/S of 0.29. Recent news highlights strategic AI investments in pharmacy services and positive sector sentiment.
The investment case centers on undervaluation, earnings momentum, and dividend yield, though risks include regulatory challenges and moderating cash flow. With a consensus price target of $339.82 implying 11.6% upside, Wall Street maintains a bullish stance, but investors should weigh execution risks against growth initiatives.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $76.27, down 4.38% today amid bearish technical signals. The ETF faces high volatility (~50% annualized) and significant China concentration risk, though recent news highlights growing institutional interest in rare earths as critical for AI and defense infrastructure. Technical indicators show oversold RSI readings but dominant bearish moving average signals.
Outlook remains speculative given geopolitical supply chain dependencies and commodity price sensitivity. Investment appeal hinges on long-term rare earth demand growth from technology and energy transitions, but risks include China export controls and ETF liquidity constraints. Current levels near support at $76 may attract tactical buyers despite near-term bearish momentum.
Trailing returns across standard periods
Latest headlines on both assets
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →